PROX1 and neoplasm: Constitutive overexpression of Prox1-IRES-GFP led to fewer tumor nodules at the endpoint (6.7 versus 39.5 nodules), and all resulting tumors were GFP-negative, indicating selection against Prox1 OE (Fig. 2i and Extended Data Fig. 3c,d).